BiotechTube

AQUAVAN® (fospropofol disodium) Injection + Midazolam HCI

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Conscious Sedation

Conditions

Conscious Sedation

Trial Timeline

Mar 1, 2006 → Oct 1, 2006

NCT ID
NCT00261599

About AQUAVAN® (fospropofol disodium) Injection + Midazolam HCI

AQUAVAN® (fospropofol disodium) Injection + Midazolam HCI is a phase 3 stage product being developed by Eisai for Conscious Sedation. The current trial status is completed. This product is registered under clinical trial identifier NCT00261599. Target conditions include Conscious Sedation.

What happened to similar drugs?

1 of 2 similar drugs in Conscious Sedation were approved

Approved (1) Terminated (1) Active (0)
✅Dexmedetomidine + PropofolPfizerApproved
❌DexmedetomidineOrion CorporationPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00261599Phase 3Completed

Competing Products

2 competing products in Conscious Sedation

See all competitors
ProductCompanyStageHype Score
Dexmedetomidine + PropofolPfizerApproved
43
DexmedetomidineOrion CorporationPhase 3
29